Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Contract Research
Return to: PBR Home | Contract Research & Services | Contract Research

Contract Research

CSSi LifeSciences, PRC Clinical partner to provide extended clinical trial services CSSi LifeSciences formalized a strategic partnership agreement with PRC Clinical, a Silicon Valley-based CRO specializing in Clinical Trial Management. CSSi LifeSciences is specialized in strategic, marketing, and regulatory consulting, FDA advisory services, and patient recruitment services.
Contract Research & Services > Contract Research > News
Biogen enters strategic alliance to develop new Parkinson’s disease treatments By PBR Staff Writer
Biogen has formed a strategic alliance with the Parkinson’s Institute and Clinical Center to improve understanding of the underlying biology of Parkinson’s disease (PD) and discover new tools and programs to accelerate research and development of new PD treatments.
Contract Research & Services > Contract Research > News Bayer, Sprint Bioscience partner to develop new oncology drug candidates By PBR Staff Writer
Bayer HealthCare has entered into a collaboration and license agreement with the Swedish company Sprint Bioscience to research, develop and commercialize oncology drug candidates.
Contract Research & Services > Contract Research > News
See more Contract Research news

Latest Contract Research News and Insight

View all Contract Research news or find news targeted to your interests
Truly Parallel - Cell Culture
| By Eppendorf
DASGIP® Bioreactor Systems for Cell Culture Applications.
Contract Research & Services > Contract Research > White Papers
Product Brochure: Most Compact
| By Eppendorf
DASbox® Mini Bioreactor System for Cell Culture and Microbiology.
Contract Research & Services > Contract Research > White Papers
Merck Serono extends collaboration with BioMed X
BioMed X Innovation Center announced that they have extended their collaboration with Merck Serono, the biopharmaceuticals business of Merck, on new approaches for cancer therapy.
Contract Research & Services > Contract Research > News
PRA Health Sciences Launches New Initiative To Bolster Workforce
PRA Health Sciences (PRA) (NASDAQ: PRAH) is looking to hire new talent. To help attract potential employees from around the world, PRA, a leading global contract research organization (CRO), is launching a new Candidate Experience initiative. Just as PRA is finding innovative ways to improve the clinical development process, it is also developing creative strategies to meet the ever-growing need to identify highly skilled clinical research employees.
Contract Research & Services > Contract Research > Press Releases
Simulations Plus extends research deal with NIEHS
Simulations Plus, the premier provider of simulation and modeling software and consulting services for all phases of pharmaceutical/chemical research and development, announced that it has extended the Material Transfer Agreement (MTA) with the Division of the National Toxicology Program (DNTP) of the US National Institute of Environmental Health Sciences (NIEHS) for an additional three year term.
Contract Research & Services > Contract Research > News
Cerulean doses first patient in Phase Ib trial of CRLX101-paclitaxel combination in relapsed ovarian cancer
By PBR Staff Writer
US-based Cerulean Pharma has dosed first patient in an open label Phase Ib clinical trial of CRLX101, a nanoparticle-drug conjugate (NDC), in combination with weekly paclitaxel to treat relapsed ovarian cancer.
Contract Research & Services > Contract Research > News
MGB Biopharma begins Phase I trial of oral MGB-BP-3 to treat clostridium difficile infections
By PBR Staff Writer
Scotland-based biopharmaceutical firm MGB Biopharma has dosed the first group of healthy male volunteers in a Phase I clinical trial evaluating the safety and tolerability of an oral formulation of MGB-BP-3, to treat Clostridium difficile infections.
Contract Research & Services > Contract Research > News
Forge enters into pilot study with Janssen to discover new metalloprotein inhibitors
By PBR Staff Writer
US-based biotechnology start-up Forge Therapeutics has entered into a pilot study with Janssen Research & Development (JRD) to examine the Forge's chemistry platform in the discovery of new metalloprotein inhibitors.
Contract Research & Services > Contract Research > News
View all Contract Research news or find news targeted to your interests